Literature DB >> 16301662

A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection.

Sandra G Morrison1, Richard P Morrison.   

Abstract

Acquired immunity to murine Chlamydia trachomatis genital tract reinfection has long been assumed to be solely dependent on cell-mediated immunity. However, in this study, we identify a previously unrecognized protective role for Ab. Immunity develops in Ab-deficient mice following the resolution of primary chlamydial genital infection. Subsequent depletion of CD4+ T cells, but not CD8+ T cells, in those immune Ab-deficient mice before secondary infectious challenge, resulted in an infection that did not resolve. Passive immunization with immune (convalescent) serum conferred a marked level of protective immunity to reinfection, which was characterized by a striking decrease in bacterial shedding, from >100,000 inclusion forming units to fewer than 10 inclusion forming units, and a shortened duration of infection. Furthermore, mAbs to the chlamydial major outer membrane protein and LPS conferred significant levels of immunity to reinfection and reduced chlamydial shedding by >100-fold. Anti-heat shock protein 60 mAb had no protective effect. In contrast to the marked protective efficacy of immune serum on reinfection, the course of primary infection was essentially unaltered by the passive transfer of immune serum. Our results convincingly demonstrate that Abs contribute importantly to immunity to chlamydial genital tract reinfection, and that Ab-mediated protection is highly dependent on CD4+ T cell-mediated adaptive changes that occur in the local genital tract tissues during primary infection. These results impact our understanding of immunity to chlamydial genital infection and may provide important insight into vaccine development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301662      PMCID: PMC3514507          DOI: 10.4049/jimmunol.175.11.7536

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  In vitro neutralization of Chlamydia trachomatis by monovalent Fab antibody specific to the major outer membrane protein.

Authors:  H Su; H D Caldwell
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

2.  Protective role of serum antibody in immunity to chlamydial genital infection.

Authors:  R G Rank; B E Batteiger
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

3.  Protective monoclonal antibodies to Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein determinants.

Authors:  Y X Zhang; S J Stewart; H D Caldwell
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

4.  Functional and structural mapping of Chlamydia trachomatis species-specific major outer membrane protein epitopes by use of neutralizing monoclonal antibodies.

Authors:  E M Peterson; X Cheng; B A Markoff; T J Fielder; L M de la Maza
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

5.  Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines.

Authors:  K H Ramsey; R G Rank
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

6.  Monoclonal antibody against a genus-specific antigen of Chlamydia species: location of the epitope on chlamydial lipopolysaccharide.

Authors:  H D Caldwell; P J Hitchcock
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

7.  Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis.

Authors:  Y X Zhang; S Stewart; T Joseph; H R Taylor; H D Caldwell
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

8.  Monoclonal antibodies define genus-specific, species-specific, and cross-reactive epitopes of the chlamydial 60-kilodalton heat shock protein (hsp60): specific immunodetection and purification of chlamydial hsp60.

Authors:  Y Yuan; K Lyng; Y X Zhang; D D Rockey; R P Morrison
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

9.  In vitro neutralization of Chlamydia trachomatis with monoclonal antibody to an epitope on the major outer membrane protein.

Authors:  R Peeling; I W Maclean; R C Brunham
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

10.  Identification and characterization of T helper cell epitopes of the major outer membrane protein of Chlamydia trachomatis.

Authors:  H Su; R P Morrison; N G Watkins; H D Caldwell
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more
  117 in total

1.  Protective immunity against mouse upper genital tract pathology correlates with high IFNγ but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway.

Authors:  Chunxue Lu; Hao Zeng; Zhihong Li; Lei Lei; I-Tien Yeh; Yimou Wu; Guangming Zhong
Journal:  Vaccine       Date:  2011-11-10       Impact factor: 3.641

2.  Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.

Authors:  Weidang Li; Ashlesh K Murthy; M Neal Guentzel; James P Chambers; Thomas G Forsthuber; J Seshu; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

Review 3.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

4.  A Chlamydia trachomatis OmcB C-terminal fragment is released into the host cell cytoplasm and is immunogenic in humans.

Authors:  Manli Qi; Siqi Gong; Lei Lei; Quanzhong Liu; Guangming Zhong
Journal:  Infect Immun       Date:  2011-03-21       Impact factor: 3.441

5.  Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

Authors:  F O Eko; D N Okenu; U P Singh; Q He; C Black; J U Igietseme
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

6.  Induction of immune memory by a multisubunit chlamydial vaccine.

Authors:  F O Eko; E Ekong; Q He; C M Black; J U Igietseme
Journal:  Vaccine       Date:  2010-12-22       Impact factor: 3.641

7.  The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells.

Authors:  Cathi Murphey; Ashlesh K Murthy; Patricia A Meier; M Neal Guentzel; Guangming Zhong; Bernard P Arulanandam
Journal:  Cell Immunol       Date:  2006-11-20       Impact factor: 4.868

8.  Frequency of Chlamydia trachomatis-specific T cell interferon-γ and interleukin-17 responses in CD4-enriched peripheral blood mononuclear cells of sexually active adolescent females.

Authors:  Romina Barral; Ruchi Desai; Xiaojing Zheng; Lauren C Frazer; Gina S Sucato; Catherine L Haggerty; Catherine M O'Connell; Matthew A Zurenski; Toni Darville
Journal:  J Reprod Immunol       Date:  2014-02-01       Impact factor: 4.054

9.  IL-6-mediated signaling pathways limit Chlamydia muridarum infection and exacerbate its pathogenicity in the mouse genital tract.

Authors:  Xin Sun; Qi Tian; Luying Wang; Min Xue; Guangming Zhong
Journal:  Microbes Infect       Date:  2017-08-31       Impact factor: 2.700

10.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.